HK Stock Market Move | AKESO (09926) surges more than 8% again, Cardunili and Ivorsina included in the latest medical insurance catalog, expected to see a significant increase in 25 years.

AKESO (09926) rose over 8% again, rising 8.16% to HK$80.2 as of the time of writing, with a turnover of HK$534 million. CMB International released a research report stating that AKESO's 2024 performance reflects strong cost control. Total revenue for the period was RMB 21 billion, with product sales revenue of RMB 20 billion, an increase of 25% year-on-year. The bank predicts that AKESO's product sales this year will increase by 60% to RMB 33 billion, benefiting from the inclusion of AK104 and AK112 in China's national medical insurance at the beginning of the year. Huayuan Securities pointed out that Cardunili and Ivosi were successfully included in medical insurance for the first time in 2024, and sales focus has shifted to the core in-hospital market, which is expected to improve drug accessibility, significantly reduce patient drug burden, and have the potential for high-speed sales growth in 25 years. JPMorgan Chase believes that the highly differentiated efficacy and safety of AK112 and AK104 will help expand indications and drive sales growth.